New Jersey is currently home to 1660 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT06139107
Recruiting
This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess the benefits of concurrent use of these treatments in a specific participant population, focusing on their safety and tolerability. The hypothesis is that the combination therapy will be well-tolerated, providing valuable insights... Read More
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
04/01/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Breast Cancer
Register for Updates
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT05559164
Recruiting
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey
Conditions: Cardiac Toxicity, Early-stage Breast Cancer
Register for Updates
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
NCT04855825
Recruiting
The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2024
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder, Cognitive Impairment
Register for Updates
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954
Recruiting
Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Summit Health, Florham Park, New Jersey
Conditions: Malignant Neoplasm of Breast
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA
NCT05519072
Recruiting
This study aims to show that lack of antibiotic prophylaxis to those undergoing bladder Botox injections is not significantly inferior to administering prophylaxis. By proving this, the investigators aim to decrease antibiotic use in this setting to combat the growing issue of antibiotic resistance. Participants will be randomized to antibiotic or no treatment arm. Those randomized to the treatment arm will receive oral antibiotics for 2 days pre-treatment, on the treatment day, and 2 days post... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Atlantic Health, Morristown, New Jersey
Conditions: Antibiotic Prophylaxis
Register for Updates
Behavioral Exposure for Introceptive Tolerance RCT
NCT05398276
Recruiting
Behavioral Exposure for Interoceptive Tolerance (BE-FIT) is a mechanism-informed behavioral intervention to target exercise anxiety. The three primary components of BE-FIT include: (1) exposure to feared bodily sensations and exercise; (2) prevention of safety behavior use before/during/after exercise, and (3) use of a wrist-worn activity monitor for physical activity (PA) feedback and activity goal setting. Evidence from the investigators' Stage I trial indicated that BE-FIT is feasible, accept... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/25/2024
Locations: RWJ Cardiac Rehab at East Brunswick, East Brunswick, New Jersey
Conditions: Exercise Sensitivity, Introceptive Exposure, Anxiety, Cardiac Rehabilitation
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Premier Health Research, Sparta, New Jersey
Conditions: NASH, Cirrhosis, Liver
Register for Updates
Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
NCT05180032
Recruiting
The objective of the proposed work is to determine whether administration for 12 months of romosozumab (evenity) followed by 12 months of denosumab (prolia) will maintain bone mass at the knee in subjects with chronic SCI.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/21/2024
Locations: Kessler Institute for Rehabilitation, West Orange, New Jersey
Conditions: Osteoporosis, Spinal Cord Injuries
Register for Updates
Modulating Reward Learning Using Transcranial Magnetic Stimulation
NCT06323057
Recruiting
Our specific aim is to examine the effects of TMS on reward processing during goal-directed behavior. In these experiments the investigators will utilize a scalp-recorded brain oscillation called frontal midline theta that is believed to index the sensitivity of the cingulate cortex to reward feedback. Here the investigators will asked whether this electrophysiological signal can be modulated up or down using TMS while participants engage in decision making tasks, and if so, whether it would aff... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/20/2024
Locations: Rutgers University - Newark, Newark, New Jersey
Conditions: Behavior
Register for Updates
Adapting BA for Minimally Verbal Autistic Adults
NCT06064422
Recruiting
The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Rutgers University - New Brunswick, Piscataway, New Jersey
Conditions: Autism, Depression, Autism Spectrum Disorder With Impaired Functional Language, Autism Spectrum Disorder
Register for Updates
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT05806931
Recruiting
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey
Conditions: Colon Cancer, Rectal Cancer
Register for Updates